Aegerion Pharmaceuticals

novelion.com

Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics, is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Headquartered in Cambridge, Massachusetts, Aegerion employs about 200 people in a number of countries throughout the world.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

PACE® LIFE SCIENCES ACQUIRES BIOPHARMA GLOBAL, EXPANDING FDA REGULATORY AFFAIRS STRATEGY AND CONSULTING CAPABILITIES

Pace® Life Sciences | September 09, 2022

news image

Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization and a subsidiary of Pace®, a science and technology company, announced today that it has acquired Biopharma Global. Biopharma specializes in full-service regulatory support for orphan products to treat rare diseases and non-orphan products to treat indications with unmet medical needs. "Pace® provides great value in our marketplace through our technic...

Read More

Business Insights

AGILENT ANNOUNCES THE INNOVATIVE SEAHORSE XF PRO ANALYZER

Agilent Technologies Inc. | January 25, 2022

news image

Agilent Technologies Inc. announced the release of the Agilent Seahorse XF Pro Analyzer, featuring new pharma-oriented workflow solutions incorporating advanced experimental design and analysis tools. With enhanced performance, more robust and efficient workflows, and an optimized user experience, the XF Pro enables operators at any skill level to access the most advanced cellular metabolism analysis technology for understanding cellular fate, fitness, and function. Preclinical th...

Read More

CLARUS EQUIPS TOP PHARMACEUTICAL COMPANY, ASTRAZENECA, WITH INNOVATIVE THERMOBILE BOARDS IN THE FIGHT AGAINST COVID-19

Clarus | April 22, 2020

news image

Clarus, the industry leader in glassboard innovation and creator of the new TherMobile, a non-porous mobile board that serves as a protective shield during the health screening process, is successfully supporting AstraZeneca's efforts in keeping their essential employees safe while continuing to work during the COVID-19 crisis. "We initially developed TherMobile as a way to keep our own employees safe while implementing employee temperature screening at our facility," said Marc Man...

Read More

Business Insights

ASTELLAS AND SUTRO BIOPHARMA ANNOUNCE WORLDWIDE STRATEGIC COLLABORATION TO ADVANCE NOVEL IMMUNOSTIMULATORY ANTIBODY-DRUG CONJUGATES (IADCS)

Sutro Biopharma, Inc.; Astellas Pharma Inc. | June 28, 2022

news image

Astellas Pharma Inc. and Sutro Biopharma, Inc. announced a worldwide, strategic collaboration and licensing agreement focused on the discovery and development of novel immunostimulatory antibody-drug conjugates. The collaboration leverages the unique cancer-fighting potential of iADCs as a novel modality, enabled by Sutro’s ability to engineer complex conjugated antibodies, and Astellas’ global oncology R&D expertise. “We are delighted t...

Read More
news image

Pharma Tech

PACE® LIFE SCIENCES ACQUIRES BIOPHARMA GLOBAL, EXPANDING FDA REGULATORY AFFAIRS STRATEGY AND CONSULTING CAPABILITIES

Pace® Life Sciences | September 09, 2022

Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization and a subsidiary of Pace®, a science and technology company, announced today that it has acquired Biopharma Global. Biopharma specializes in full-service regulatory support for orphan products to treat rare diseases and non-orphan products to treat indications with unmet medical needs. "Pace® provides great value in our marketplace through our technic...

Read More
news image

Business Insights

AGILENT ANNOUNCES THE INNOVATIVE SEAHORSE XF PRO ANALYZER

Agilent Technologies Inc. | January 25, 2022

Agilent Technologies Inc. announced the release of the Agilent Seahorse XF Pro Analyzer, featuring new pharma-oriented workflow solutions incorporating advanced experimental design and analysis tools. With enhanced performance, more robust and efficient workflows, and an optimized user experience, the XF Pro enables operators at any skill level to access the most advanced cellular metabolism analysis technology for understanding cellular fate, fitness, and function. Preclinical th...

Read More
news image

CLARUS EQUIPS TOP PHARMACEUTICAL COMPANY, ASTRAZENECA, WITH INNOVATIVE THERMOBILE BOARDS IN THE FIGHT AGAINST COVID-19

Clarus | April 22, 2020

Clarus, the industry leader in glassboard innovation and creator of the new TherMobile, a non-porous mobile board that serves as a protective shield during the health screening process, is successfully supporting AstraZeneca's efforts in keeping their essential employees safe while continuing to work during the COVID-19 crisis. "We initially developed TherMobile as a way to keep our own employees safe while implementing employee temperature screening at our facility," said Marc Man...

Read More
news image

Business Insights

ASTELLAS AND SUTRO BIOPHARMA ANNOUNCE WORLDWIDE STRATEGIC COLLABORATION TO ADVANCE NOVEL IMMUNOSTIMULATORY ANTIBODY-DRUG CONJUGATES (IADCS)

Sutro Biopharma, Inc.; Astellas Pharma Inc. | June 28, 2022

Astellas Pharma Inc. and Sutro Biopharma, Inc. announced a worldwide, strategic collaboration and licensing agreement focused on the discovery and development of novel immunostimulatory antibody-drug conjugates. The collaboration leverages the unique cancer-fighting potential of iADCs as a novel modality, enabled by Sutro’s ability to engineer complex conjugated antibodies, and Astellas’ global oncology R&D expertise. “We are delighted t...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us